{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial Comparing Modified Ligation Procedure and Stapled Haemorrhoidectomy for Symptomatic Haemorrhoids"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-centre, randomised, single-blind trial enrolled patients aged 18\u201380 years with symptomatic second- to fourth-degree haemorrhoids from May 2018 to September 2021"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients aged 18\u201380 years with symptomatic second- to fourth-degree haemorrhoids from May 2018 to September 2021"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to MLPPH or SH"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the safety, efficacy, and cost-effectiveness of a modified ligation procedure for prolapsed haemorrhoids (MLPPH) compared to stapled haemorrhoidectomy (SH) in patients with symptomatic haemorrhoids."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 6-month cure rate."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was stratified by haemorrhoid grade using a computer-generated sequence, with allocation concealment via opaque envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not applied to participants or clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 187 patients screened, 133 were randomised (67 to MLPPH, 66 to SH)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "One patient in the MLPPH group was excluded, and two were lost to follow-up."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 6-month cure rate was significantly higher in the MLPPH group (90.6%) compared to the SH group (69.7%) (P = 0.003)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ChiCTR1800015928."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}